The Efficiency of Docetaxel Chemotherapy on Castration Resistant Prostate Cancer: Singe Center Experience

SÜER E., Hamidi N., GÖKCE M. İ., BALTACI S.

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, cilt.16, sa.3, ss.77-80, 2017 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/uob.821
  • Dergi Adı: UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.77-80
  • Anahtar Kelimeler: Docetaxel, prognosis, prostate cancer, survival, MITOXANTRONE PLUS PREDNISONE, MEN, ENZALUTAMIDE, SURVIVAL
  • Ankara Üniversitesi Adresli: Evet

Özet

Objective: Prostate cancer (PCa) is the second most commonly seen cancer type worldwide. Mortality due to PCa is mostly linked to the development of castration resistant PCa (CRPC). In these patients, the main treatment option is docetaxel based chemotherapy (DBC). In this study, we aimed to present our retrospective series.